228 related articles for article (PubMed ID: 31929109)
1. Analyses of the oncogenic BRAF
Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
[TBL] [Abstract][Full Text] [Related]
2. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
[TBL] [Abstract][Full Text] [Related]
4. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
Rebocho AP; Marais R
Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515
[TBL] [Abstract][Full Text] [Related]
5. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
Hu J; Yu H; Kornev AP; Zhao J; Filbert EL; Taylor SS; Shaw AS
Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6067-72. PubMed ID: 21441104
[TBL] [Abstract][Full Text] [Related]
6. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.
Holderfield M; Merritt H; Chan J; Wallroth M; Tandeske L; Zhai H; Tellew J; Hardy S; Hekmat-Nejad M; Stuart DD; McCormick F; Nagel TE
Cancer Cell; 2013 May; 23(5):594-602. PubMed ID: 23680146
[TBL] [Abstract][Full Text] [Related]
7. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Monaco KA; Delach S; Yuan J; Mishina Y; Fordjour P; Labrot E; McKay D; Guo R; Higgins S; Wang HQ; Liang J; Bui K; Green J; Aspesi P; Ambrose J; Mapa F; Griner L; Jaskelioff M; Fuller J; Crawford K; Pardee G; Widger S; Hammerman PS; Engelman JA; Stuart DD; Cooke VG; Caponigro G
Clin Cancer Res; 2021 Apr; 27(7):2061-2073. PubMed ID: 33355204
[TBL] [Abstract][Full Text] [Related]
8. Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.
Gunderwala AY; Nimbvikar AA; Cope NJ; Li Z; Wang Z
ACS Chem Biol; 2019 Jul; 14(7):1471-1480. PubMed ID: 31243962
[TBL] [Abstract][Full Text] [Related]
9. The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF.
Yuan J; Ng WH; Yap J; Chia B; Huang X; Wang M; Hu J
J Biol Chem; 2018 Sep; 293(37):14276-14284. PubMed ID: 30030377
[TBL] [Abstract][Full Text] [Related]
10. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
Smalley KS; Xiao M; Villanueva J; Nguyen TK; Flaherty KT; Letrero R; Van Belle P; Elder DE; Wang Y; Nathanson KL; Herlyn M
Oncogene; 2009 Jan; 28(1):85-94. PubMed ID: 18794803
[TBL] [Abstract][Full Text] [Related]
11. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
[TBL] [Abstract][Full Text] [Related]
12. Allosteric activation of functionally asymmetric RAF kinase dimers.
Hu J; Stites EC; Yu H; Germino EA; Meharena HS; Stork PJS; Kornev AP; Taylor SS; Shaw AS
Cell; 2013 Aug; 154(5):1036-1046. PubMed ID: 23993095
[TBL] [Abstract][Full Text] [Related]
13. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
Chatelle CV; Hövermann D; Müller A; Wagner HJ; Weber W; Radziwill G
Sci Rep; 2016 Mar; 6():23713. PubMed ID: 27025703
[TBL] [Abstract][Full Text] [Related]
14. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.
Yao Z; Gao Y; Su W; Yaeger R; Tao J; Na N; Zhang Y; Zhang C; Rymar A; Tao A; Timaul NM; Mcgriskin R; Outmezguine NA; Zhao H; Chang Q; Qeriqi B; Barbacid M; de Stanchina E; Hyman DM; Bollag G; Rosen N
Nat Med; 2019 Feb; 25(2):284-291. PubMed ID: 30559419
[TBL] [Abstract][Full Text] [Related]
15. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
Wang P; Laster K; Jia X; Dong Z; Liu K
Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
[TBL] [Abstract][Full Text] [Related]
16. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
17. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK.
Brennan DF; Dar AC; Hertz NT; Chao WC; Burlingame AL; Shokat KM; Barford D
Nature; 2011 Apr; 472(7343):366-9. PubMed ID: 21441910
[TBL] [Abstract][Full Text] [Related]
18. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
19. Raf inhibitors target ras spatiotemporal dynamics.
Cho KJ; Kasai RS; Park JH; Chigurupati S; Heidorn SJ; van der Hoeven D; Plowman SJ; Kusumi A; Marais R; Hancock JF
Curr Biol; 2012 Jun; 22(11):945-55. PubMed ID: 22560614
[TBL] [Abstract][Full Text] [Related]
20. Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization.
Liau NPD; Wendorff TJ; Quinn JG; Steffek M; Phung W; Liu P; Tang J; Irudayanathan FJ; Izadi S; Shaw AS; Malek S; Hymowitz SG; Sudhamsu J
Nat Struct Mol Biol; 2020 Feb; 27(2):134-141. PubMed ID: 31988522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]